Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
NCT ID: NCT01044719
Last Updated: 2010-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
240 participants
INTERVENTIONAL
2010-01-31
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
NCT02526004
Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
NCT02421120
Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
NCT00153634
LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
NCT02840136
Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis
NCT04335370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10 days
Ceftazidime
Ceftazidime 2g TDS IV
Tobramycin
Tobramycin 7mg/kg/day OD IV
Meropenem
Meropenem 2g TDS IV
14 days
Ceftazidime
Ceftazidime 2g TDS IV
Tobramycin
Tobramycin 7mg/kg/day OD IV
Meropenem
Meropenem 2g TDS IV
21 days
Ceftazidime
Ceftazidime 2g TDS IV
Tobramycin
Tobramycin 7mg/kg/day OD IV
Meropenem
Meropenem 2g TDS IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceftazidime
Ceftazidime 2g TDS IV
Tobramycin
Tobramycin 7mg/kg/day OD IV
Meropenem
Meropenem 2g TDS IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Cystic Fibrosis
* Presenting with Infective exacerbation
Exclusion Criteria
* Allergy to study medications
* Intolerance of aminoglycoside antibiotics
* Pseudomonas resistant to study antibiotics
* On the active transplant list or FEV1\<20% predicted
* Pregnancy/breast-feeding
* Co-existent ABPA requiring a change in treatment
* Co-existent mycobacterial infection
* A previous participant in the study
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Imperial College London
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Margaret Hodson, MD FRCP DA
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cystic Fibrosis, Royal Brompton Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RBHADS001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.